Black Diamond Therapeutics, Inc. (BDTX)
NASDAQ: BDTX · Real-Time Price · USD
2.150
+0.100 (4.88%)
At close: Mar 6, 2026, 4:00 PM EST
2.110
-0.040 (-1.86%)
After-hours: Mar 6, 2026, 7:02 PM EST
BDTX Employees
Black Diamond Therapeutics had 24 employees as of December 31, 2024. The number of employees decreased by 30 or -55.56% compared to the previous year.
Employees
24
Change (1Y)
-30
Growth (1Y)
-55.56%
Revenue / Employee
$2,916,667
Profits / Employee
$895,750
Market Cap
122.50M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Codexis | 188 |
| Gossamer Bio | 145 |
| Inovio Pharmaceuticals | 134 |
| Precision BioSciences | 67 |
| Equillium | 35 |
| Oncolytics Biotech | 28 |
| Genelux | 24 |
| Coya Therapeutics | 8 |
BDTX News
- 4 days ago - Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Benzinga
- 3 months ago - Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - GlobeNewsWire
- 3 months ago - Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout - Seeking Alpha
- 4 months ago - Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - 4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - Benzinga
- 6 months ago - Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash - Seeking Alpha